Compositions and methods to prevent cancer with cupredoxins

Details Compositions and methods to prevent cancer with cupredoxins Compositions and methods to prevent cancer with cupredoxins

2007-09-13

2009-11-17

Carlson, Karen Cochrane (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000

Reexamination Certificate

active

07618939

ABSTRACT:
The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin fromPseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The present invention further relates to compositions that may comprise cupredoxin(s), and/or variants, derivatives or structural equivalents of cupredoxins, that retain the ability to inhibit the development of premalignant lesions in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to prevent the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.

REFERENCES:
patent: 4897268 (1990-01-01), Tice et al.
patent: 5075109 (1991-12-01), Tice et al.
patent: 5811128 (1998-09-01), Tice et al.
patent: 5814344 (1998-09-01), Tice et al.
patent: 5820883 (1998-10-01), Tice et al.
patent: 5853763 (1998-12-01), Tice et al.
patent: 5928647 (1999-07-01), Rock
patent: 5942252 (1999-08-01), Tice et al.
patent: 7084105 (2006-08-01), Chakrabarty et al.
patent: 7301010 (2007-11-01), Chakrabarty et al.
patent: 7338766 (2008-03-01), Chakrabarty et al.
patent: 7381701 (2008-06-01), Chakrabarty et al.
patent: 2006/0040269 (2006-02-01), Chakrabarty et al.
patent: 2006/0149037 (2006-07-01), Chakrabarty et al.
patent: 2005018662 (2005-03-01), None
Yamada et al. 2002. Bacterial redox protein azuran, tumor suppressor protein p53, and regression of cancer. Proc. Natl. Acad. Sci., 99(22): 14098-14103.
Farver et al. 1981; Affinity labeling of an electron transfer pathway in azurin by Cr(II) ions. Israel Journal of Chemistry. 21: 13-17.
van Gastel et al. published Mar. 6, 2002, online Feb. 9, 2002; An ab initio quantum-chemical study of the blue-copper site if azurin. J. Am. Chem Soc. 124(9): 2035-2041.
Yamada et al., PNAS 99(22): 14098-14103 (2002).
Yamada et al., Infect lmmun. 70: 7054-7062.
Yamada et al., Cell. Microbial. 7: 1418-1431 (2005).
Yamada et al., Cell Cycle 3: 1182-1187 (2004).
Punj et al., Oncogene. 23: 2367-2378 (2004).
Jang et al., Science 275: 218-220 (1997).
Metha, Eur. J. Cancer 36: 1275-1282 (2000).
Mehta et al., J. Natl. Cancer Inst. 89: 212-219 (1997).
Mehta et al. J Natl. Cancer Inst. 93: 1103-1106(2001).
Mehta et al., Meth Cell Sci 19: 19-24(1997).
Ghadiri & Fernholz, J. Am. Chem. Soc., 112: 9633-9635 (1990).
Zaborina et al. Microbiology 146: 2521-2530 (2000).
Futaki et al., J. Biol. Chem. 276(8): 5836-40 (2001).
Labrie et al., Clin. Invest. Med. 13(5): 275-8 (1990).
Schafmeister et al. J. Am. Chem. Soc. 122: 5891-5892 (2000).
Walenski et al., Science 305:1466-1470 (2004).
Papo et al., Cancer Res. 64(16): 5779-86 (2004).
Miller et al., BiochemPharmacol. 36(1): 169-76, (1987).
Lee et al., J. Pept. Res. 63(2): 69-84(2004).
Monk et al., BioDrugs 19(4): 261-78 (2005).
Defreest et al., J. Pept. Res. 63(5): 409-19 (2004).
Toth et al., (Developmental Cell 1: 82-92 (2001)).
Gough & Clothia, Structure 12: 917-925 (2004).
De Rienzo et al., Protein Science 9: 1439-1454 (2000).
Kuwabara, Genes and Development 17: 155-161 (2003).
Murphy et al., J. Mol. Biol. 315: 859-871 (2002).
Redinbo et al., J. Bioenerg. Biomembr. 26: 49-66 (1994).
Walter, R.L. et al., J. Mol. Biol. 263: 730-51 (1996).
Van Dreissche et al., Protein Science 8: 947-957 (1999).
Bond et al., J. Mol. Biol. 306: 47-67 (2001).
McManus et al. J. Boil. Chem. 267: 6531-6540 (1992).
Koch et al. J Am. Chem. Soc. 127: 158-166 (2005).
Hart et al., Protein Science 5: 2175-2183 (1996).
Guss et al., J. Mol. Biol. 262: 686-705 (1996).
Cuzick, Breast 12: 405-411 (2003).
Huang et al., Am J. Epidemiol 151: 703-714 (2000).
Thiberville et al., Cancer Res. 55: 5133-5139 (1995).
Mao et al., J. Natl. Cancer Inst. 89: 857-862 (1997).
Tsao et al., CA Clln. Cancer J. Clin. 54: 150-180 (2004).
Ulmer et al., Science 259: 1745-1749(1993).
Kaufman, Methods Enzymol. 185: 487-511(1990).
Carter, Biochem J. 237: 1-7 (1986).
Zoller and Smith, Methods Enzymol. 154: 329-350 (1987).
Wells et al. Gene 34: 315-323 (1985).

Affiliated with

Also associated with

Rating

Compositions and methods to prevent cancer with cupredoxins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods to prevent cancer with cupredoxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods to prevent cancer with cupredoxins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4075230